Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. Looking to assess whether Ocaliva ...
Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results